secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001493152-24-029514
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for Processa's NGC-Cap Phase 2 trial in breast cancer
--------------------------------------------------------------------

- FDA cleared IND for NGC-Cap Phase 2 trial in advanced/metastatic breast cancer.
- Phase 2 trial enrollment expected to begin in Q3 2024.
- Initial data from the Phase 2 trial expected mid-2025.
- Phase 1b showed NGC-Cap provides 5-10x more 5-FU exposure and better safety than capecitabine alone.
- Trial is global, open-label, adaptive design with 60-90 patients; compares two doses of NGC-Cap to capecitabine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224029514/0001493152-24-029514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224029514/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-029514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer